On June 26th, listed company Yinghe Technology responded to investor inquiries on a Q&A platform, stating that its subsidiary Shenzhen SKE Technology Co., Ltd. is engaged in the e-cigarette business. SKE has been vigorously promoting its own brand since 2022 and has achieved good development in the brand business in the UK and other European countries with its product and technology advantages.
The following is the original text of the Q&A session.
？ Question: The current market is concerned about potential overcapacity in the lithium battery industry. What is your company's perspective on this issue? Does your company have any business layout or strategic planning outside the lithium battery industry?
The company responded by saying that in the lithium battery business, while maintaining a leading market share domestically, it will continue to expand overseas markets and actively seize development opportunities brought about by new technologies and structural demand growth. In the non-lithium battery business, its subsidiary Shenzhen SKE Technology Co., Ltd. is engaged in the e-cigarette business. SKE has been vigorously developing its own brand since 2022, leveraging its product and technology advantages to achieve good development in the brand business in the UK and other European countries. In addition, the company has been actively researching and exploring new fields in order to achieve diversified business development, although no specific new fields for expansion have been determined at this time. Please continue to follow us. Thank you!
Disclaimer
This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.
Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.
The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.
This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.
Copyright Notice
This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.
No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.
For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.
AI-Assisted Translation and Editing Notice
Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.
Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.
